CARTO® 3 System and Real Time Intracardiac Ultrasound (IUAF)

This study is currently recruiting participants.
Verified February 2013 by Biosense Webster, Inc.
Sponsor:
Information provided by (Responsible Party):
Biosense Webster, Inc.
ClinicalTrials.gov Identifier:
NCT01716663
First received: October 19, 2012
Last updated: April 30, 2013
Last verified: February 2013
  Purpose

This is a prospective, multicenter, non-randomized observational study of subjects 18 years and older undergoing RF ablation with drug refractory recurrent symptomatic paroxysmal Atrial Fibrillation (AF).


Condition Intervention
Atrial Fibrillation
Paroxysmal AF
Device: Catheter Ablation

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study

Resource links provided by NLM:


Further study details as provided by Biosense Webster, Inc.:

Primary Outcome Measures:
  • Fluoroscopy Time [ Time Frame: Day 0 ] [ Designated as safety issue: No ]
    The fluoroscopy time will be measured for each phase (access, mapping, ablation, and validation) of the procedure.


Secondary Outcome Measures:
  • Procedure Time [ Time Frame: Day 0 ] [ Designated as safety issue: No ]
    The procedure time will be measured for each phase (access, mapping, ablation, and validation) of the procedure.

  • Acute Success [ Time Frame: Day 0 ] [ Designated as safety issue: No ]
    Acute success will be measured via confirmation of pulmonary vein isolation method.

  • Safety [ Time Frame: Within 7 days of the procedure ] [ Designated as safety issue: Yes ]
    Procedural complications, electrocardiogram abnormalities and adverse events.

  • Number of Radiofrequency (RF) Applications [ Time Frame: Day 0 ] [ Designated as safety issue: No ]
    RF application will be measured by number of times delivered during the procedure.

  • Total Radiofrequency (RF) Time [ Time Frame: Day 0 ] [ Designated as safety issue: No ]
    Total RF time will be measured for the total time RF is delivered during the procedure.


Estimated Enrollment: 500
Study Start Date: October 2012
Estimated Study Completion Date: October 2013
Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Experimental: Catheter Ablation
These patients have drug refractory recurrent symptomatic paroxysmal AF, are 18 years and older, and are able and willing to provide written informed consent to participate in the study and comply with study requirements.
Device: Catheter Ablation
NAVISTAR® THERMOCOOL® SF Catheter with the CARTO® 3 System and the SOUNDSTAR® Ultrasound Catheter (with the CARTOSOUND® Software Module)
Other Name: CARTO® 3 System and Real Time Intracardiac Ultrasound

Detailed Description:

This study is purposed to measure "real world" acute procedural outcomes (procedural efficiency and acute safety) associated with use of the CARTO® 3 System and real time intracardiac ultrasound in a clinical setting in subjects with drug refractory recurrent symptomatic paroxysmal AF.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Subjects 18 years and older with drug refractory recurrent symptomatic paroxysmal AF

Criteria

Inclusion Criteria:

  • Drug refractory, recurrent symptomatic paroxysmal AF
  • Age 18 years or older
  • Patients able and willing to provide written informed consent to participate in the study and comply with study requirements

Exclusion Criteria:

  • Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause
  • Previous ablation for atrial fibrillation
  • AF episodes that last longer than 30 days
  • Uncontrolled heart failure, or NYHA Class III or IV heart failure
  • Documented intra-atrial thrombus or other abnormality on pre-ablation imaging
  • Contraindication to anticoagulation
  • Stroke, cardiac surgery, unstable angina, myocardial infarction or percutaneous coronary intervention within the past 3 months
  • Awaiting cardiac transplantation
  • Heart disease for which corrective surgery is anticipated within 6 months
  • Enrollment in other investigational drug or device study
  • Subjects unwilling to comply with protocol or follow-up requirements
  • Patients who are pregnant
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01716663

Contacts
Contact: Timothy Hentges 623-326-4343 thentges@its.jnj.com
Contact: Jamie March 909-839-8543 jmarch1@its.jnj.com

Locations
United States, Arizona
AZ Heart Rhythm Center Recruiting
Phoenix, Arizona, United States, 85006
Contact: Wendy Schwoegler, BS     480-659-7583        
Principal Investigator: Vijendra Swarup, MD            
Clinical Research Advantage, Inc. Recruiting
Phoenix, Arizona, United States, 85015
Contact: Brigit Iles     602-824-9510     bjiels@crastudies.com    
Principal Investigator: Kishlay Anand, MD            
United States, California
Good Samaritan Hospital Not yet recruiting
Los Angeles, California, United States, 90017
Contact: Lisa Fletcher     408-559-2374     lisa.fletcher1@hcahealthcare.com    
Contact: Lori Henry     408-559-2374     lori.henry@hcahealthcare.com    
Principal Investigator: Ivan Ho            
Santa Barbara Cottage Hospital Recruiting
Santa Barbara, California, United States, 93105
Contact: Samantha Yim     805-569-7461     syim@sbch.org    
Principal Investigator: Brett Gidney            
United States, Colorado
Colorado Cardiac Alliance, LLC Not yet recruiting
Colorado Springs, Colorado, United States, 80907
Contact: Susan Stoddard     719-634-6671     sstoddard@cscardiologist.com    
Principal Investigator: Christopher Cole, MD            
United States, Florida
JFK Medical Center Recruiting
Atlantis, Florida, United States, 33462
Contact: Donalyn Lamarre     561-548-1735     donalyn.lamarre@hcahealthcare.com    
Principal Investigator: Robert Fishel, MD            
Tallahassee Resesarch Institute, Inc. Recruiting
Tallahassee, Florida, United States, 32308
Contact: Patty Knap     850-431-5024     patty.knap@tmh.org    
Contact: Sharon Liebrich            
Principal Investigator: Farhat Khairallah, MD            
United States, Illinois
Provena Saint Joseph Medical Center Recruiting
Joliet, Illinois, United States, 60435
Contact: Laura Paganessi     815-773-7031     laura.paganessi@presencehealth.org    
Principal Investigator: Ahmad Jones, MD            
United States, Ohio
MediSync Clinical Research Recruiting
Cincinnati, Ohio, United States, 45212
Contact: Jeff Repper     513-533-6514     jeff.repper@medisync.com    
Principal Investigator: Shahid Baig, MD            
United States, Pennsylvania
Geisinger Wyoming Valley Medical Center Recruiting
Danville, Pennsylvania, United States, 17822
Contact: Lori Scalzo     570-808-6382     lmscalzo1@geisinger.edu    
Principal Investigator: Gopi Dandamudi, MD            
St. Mary Medical Center Recruiting
Langhorne, Pennsylvania, United States, 19047
Contact: Miki Haas     215-710-4510     mhaas@st.maryhealthcare.org    
Principal Investigator: Scott Burke, MD            
ARIA Health Not yet recruiting
Philadelphia, Pennsylvania, United States, 19114
Contact: Jane Slaterback     267-350-3136     Janeslaterbeck@ariahealth.org    
Principal Investigator: Bradley Bacik, MD            
Hospital of the University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 17104
Contact: David Phuong     215-615-0186     david.phuong@uphs.upenn.edu    
Principal Investigator: Mathew Hutchinson, MD            
Lankenau Institute for Medical Research Not yet recruiting
Wynnewood, Pennsylvania, United States, 19096
Contact: Lisa Thome     484-476-8570     thomel@mlhs.org    
Principal Investigator: Douglas Esberg, MD            
United States, Tennessee
Wellmont CVA Heart Institute Recruiting
Kingsport, Tennessee, United States, 37660
Contact: Ashley Sparks     423-230-5062     asparks@mycva.com    
Principal Investigator: Gregory Jones, MD            
United States, Texas
Scott & White Memorial Hospital Recruiting
Temple, Texas, United States, 76508
Contact: Stephanie Blue     254-724-5373     slblue@sw.org    
Principal Investigator: David Fitzgerald, MD            
United States, Utah
McKay Dee Hospital Not yet recruiting
Ogden, Utah, United States, 84403
Contact: Staci Gola         Staci.Gola@imail.org    
Contact: Jesse Whitfield     801-408-1729     Jesse.Whitfield@imail.org    
Principal Investigator: Michael Eifling, MD            
United States, Virginia
Sentara Norfolk General Hospital Recruiting
Norfolk, Virginia, United States, 23507
Contact: Linette Klevan     757-388-2425     lrklevan@sentara.com    
Principal Investigator: Philip Gentlesk            
United States, Wisconsin
Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Susan Mauermann     414-955-6749     smauerma@mcw.edu    
Principal Investigator: Marcie Berger, MD            
Sponsors and Collaborators
Biosense Webster, Inc.
Investigators
Principal Investigator: Vijendra Swarup, MD AZ Heart Rhythm Center
  More Information

No publications provided

Responsible Party: Biosense Webster, Inc.
ClinicalTrials.gov Identifier: NCT01716663     History of Changes
Other Study ID Numbers: IUAF
Study First Received: October 19, 2012
Last Updated: April 30, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Biosense Webster, Inc.:
Symptomatic paroxysmal
Atrial fibrillation
Observational
Acute procedural outcomes
Ablation

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on June 17, 2013